» Articles » PMID: 37648841

Locomotor Behavior and Memory Dysfunction Induced by 3-Nitropropionic Acid in Adult Zebrafish: Modulation of Dopaminergic Signaling

Overview
Journal Mol Neurobiol
Date 2023 Aug 30
PMID 37648841
Authors
Affiliations
Soon will be listed here.
Abstract

Huntington's disease (HD) is a progressive neurodegenerative disease characterized by neuropsychiatric disturbance, cognitive impairment, and locomotor dysfunction. In the early stage (chorea) of HD, expression of dopamine D receptors (DR) is reduced, whereas dopamine (DA) levels are increased. Contrary, in the late stage (bradykinesia), DA levels and the expression of DR and dopamine D receptors (DR) are reduced. 3-Nitropropionic acid (3-NPA) is a toxin that may replicate HD behavioral phenotypes and biochemical aspects. This study assessed the neurotransmitter levels, dopamine receptor gene expression, and the effect of acute exposure to quinpirole (DR agonist) and eticlopride (DR antagonist) in an HD model induced by 3-NPA in adult zebrafish. Quinpirole and eticlopride were acutely applied by i.p. injection in adult zebrafish after chronic treatment of 3-NPA (60 mg/kg). 3-NPA treatment caused a reduction in DA, glutamate, and serotonin levels. Quinpirole reversed the bradykinesia and memory loss induced by 3-NPA. Together, these data showed that 3-NPA acts on the dopaminergic system and causes biochemical alterations similar to late-stage HD. These data reinforce the hypothesis that DA levels are linked with locomotor and memory deficits. Thus, these findings may suggest that the use of DA agonists could be a pharmacological strategy to improve the bradykinesia and memory deficits in the late-stage HD.

References
1.
Capiluppi E, Romano L, Rebora P, Nanetti L, Castaldo A, Gellera C . Late-onset Huntington's disease with 40-42 CAG expansion. Neurol Sci. 2019; 41(4):869-876. PMC: 7160095. DOI: 10.1007/s10072-019-04177-8. View

2.
Cepeda C, Levine M . Synaptic Dysfunction in Huntington's Disease: Lessons from Genetic Animal Models. Neuroscientist. 2020; 28(1):20-40. PMC: 9332072. DOI: 10.1177/1073858420972662. View

3.
Coppen E, Jacobs M, van den Berg-Huysmans A, van der Grond J, Roos R . Grey matter volume loss is associated with specific clinical motor signs in Huntington's disease. Parkinsonism Relat Disord. 2017; 46:56-61. DOI: 10.1016/j.parkreldis.2017.11.001. View

4.
Coppen E, Roos R . Current Pharmacological Approaches to Reduce Chorea in Huntington's Disease. Drugs. 2016; 77(1):29-46. PMC: 5216093. DOI: 10.1007/s40265-016-0670-4. View

5.
Stahl C, Feigin A . Medical, Surgical, and Genetic Treatment of Huntington Disease. Neurol Clin. 2020; 38(2):367-378. DOI: 10.1016/j.ncl.2020.01.010. View